Related Experiment Videos
Revised FIGO staging system for gestational trophoblastic tumors. Recommendations regarding therapy
D P Goldstein1, I V Zanten-Przybysz, M R Bernstein
1New England Trophoblastic Disease Center, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
The Journal of Reproductive Medicine
|February 25, 1998
Summary
The revised International Federation of Gynecology and Obstetrics (FIGO) staging system for gestational trophoblastic tumors (GTT) effectively combines staging and prognosis. This system reliably predicts treatment outcomes, aiding in the selection of optimal chemotherapy protocols for GTT patients.
Area of Science:
- Gynecology
- Oncology
- Clinical Staging
Background:
- Gestational trophoblastic tumors (GTT) require accurate staging for effective treatment.
- Previous staging systems, including WHO and Hammond's classification, have limitations.
- The International Federation of Gynecology and Obstetrics (FIGO) developed a revised staging system for GTT.
Purpose of the Study:
- To evaluate the efficacy of the revised FIGO staging system for GTT.
- To determine if the revised FIGO system can predict treatment response.
- To recommend therapeutic strategies based on the revised FIGO staging.
Main Methods:
- Literature review on GTT staging systems (FIGO, WHO, Hammond).
- Analysis of treatment response to single-agent chemotherapy.
- Study included 546 patients from the New England Trophoblastic Disease Center.
Main Results:
- The revised FIGO staging system integrates anatomical staging with clinical prognostic factors.
- This revised system demonstrates reliability in predicting patient outcomes.
- The system successfully identifies patients likely to respond poorly to single-agent chemotherapy.
Conclusions:
- The revised FIGO staging system for GTT is a valuable tool for predicting treatment success.
- It accurately predicts outcomes, guiding the selection of appropriate treatment protocols.
- This system aids in optimizing patient management for gestational trophoblastic tumors.